The company is substantially boosted this progress of a novel therapy for cardiac amyloidosis, leveraging Attruby. Initial clinical information suggests potential benefits for individuals suffering by a debilitating https://bridgebio563282.ssnblog.com/40685393/bridgebio-improves-cardiac-amyloidosis-treatment-through-the-therapy